Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma

NCT02811822 is registered in ClinicalTrials.gov with GlycoMimetics Incorporated as lead sponsor.

NCT NCT02811822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02811822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma
Lead sponsor
GlycoMimetics Incorporated
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2016
Completion date
April 30, 2019
Enrollment
10 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma